trial · primary record
Setidegrasib
Non-small Cell Lung Cancer (NSCLC)
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 356 |
| Primary completion | 2030-06-30 |
| Primary endpoint | Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. as assessed by blinded independent central review (BICR) |
| Registry ID | NCT07566052 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:05.276Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07566052
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Setidegrasib · compound